immuno oncology frontiers world miami

Immunotherapy: Extending its reach, predicting responses

View on-demand our webinar exploring:

  • Optimal application of combinations, aided by appropriate patient selection based on predictive biomarkers
  • Understanding the interactions between the immune system and tumours, which deploy various mechanisms to disrupt key processes, and targeting distinct checkpoint pathways
  • Where is the potential for new clinical application across broad patient populations?

Speakers include:

  • Art Krieg, CEO, Checkmate Pharmaceuticals
  • Dr Emmett Schmidt, Executive Director, Clinical Research, Merck Sharp & Dohme
  • Dr Richard Murray, CEO, Jounce Therapeutics
  • Dr Andrea Van Elsas, Chief Scientific Officer, Aduro Biotech Europe



immunotherapy webinar
Originally Broadcasted: Friday, September 2 2016, 2:00 PM BST

  • "Great venue to solidify and harmonize on the current challenges facing this sector - in real time. The caliber of the speakers and session contents was premier. “
    Dolores Baksh
    Innovation Leader, GE Healthcare
  • “A great event to learn about the hurdles that are needed to be overcome to get through the clinic.”
    Devin Bridgen
    Scientist, strategic partnerships, SQZ Biotech
  • "It was a great opportunity to share current data and thinking about the development of therapeutics directed at modulating the immune response to cancer."
    Lance Leopold
    Vice President, Head of Oncology Development, Incyte Corporation
  • "Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field."
    Dr James Trager
    Vice President, Research & Product Development, Dendreon
  • “In the rapidly moving Advanced Therapy market, Phacilitate remains one of the premier events.”
    David James
    CEO, Scinogy